TY - JOUR
T1 - Toward a very brief quality of life enjoyment and Satisfaction Questionnaire
AU - Rush, A. John
AU - South, Charles C.
AU - Jha, Manish K.
AU - Grannemann, Bruce D.
AU - Trivedi, Madhukar H.
N1 - Funding Information:
Dr. Rush has received consulting fees from Akili, Brain Resource Inc., Compass Inc., Curbstone Consultant LLC., Emmes Corp, Holmusk, Inc., Liva-Nova, Sunovion, Takeda USA, Taj Medical; speaking fees from Liva-Nova; royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX. (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. Dr. Trivedi has received research support from NIMH, NIDA, J&J, Janssen Research and Development LLC; has served as a consultant for Alkermes Inc., Allergan, Arcadia Pharmaceuticals Inc., AstraZeneca, Lundbeck, Medscape, MSI Methylation Sciences Inc., Merck, Otsuka America Pharmaceuticals Inc., and Takeda Pharmaceuticals Inc. Dr. Jha has received contract research grant from Acadia Pharmaceutical and Janssen Research. Dr. South and Mr. Grannemann have no financial relationships to report.
Funding Information:
The STAR*D trial was funded by the National Institute of Mental Health (NIMH) under contract N01 MH-90,003 to the University of Texas Southwestern Medical Center at Dallas. NIMH had no role in the drafting or review of the manuscript or in the collection or analysis of the data.
Funding Information:
The STAR*D trial was funded by the National Institute of Mental Health (NIMH) under contract N01 MH-90,003 to the University of Texas Southwestern Medical Center at Dallas. NIMH had no role in the drafting or review of the manuscript or in the collection or analysis of the data.
Publisher Copyright:
© 2018
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Objective: To develop and evaluate a new brief self-report measure of satisfaction/quality of life in depressed outpatients. Methods: Using the Quality of Life Enjoyment and Satisfaction Questionnaire Short-Form (Q-LES-Q-SF) self-report from Step-1 (n = 2181) of the STAR*D trial, items were selected based on their magnitude of change with treatment and correlation with 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16). Psychometric analyses were conducted. Replication of scale performance was assessed with STAR*D Step-2 data (n = 250). Results: The 7 items selected (“Mini-Q-LES-Q”) rated satisfaction with work, household activities, social and family relations, leisure time activities, daily function and sense of well-being in the past week. This uni-dimensional scale captured 83–94% variance in Q-LES-Q-SF and had acceptable Item Response and Classical Test Theory characteristics. Baseline to exit percent changes in the Mini-Q-LES-Q and the QIDS-SR16 were significantly, modestly related (r = -0.552) (Step-1) and replicated (r = -0.562) (Step-2). The Mini-Q-LES-Q detected the expected improvement in satisfaction/quality of life in acute treatment, yet also identified residual deficits expected in many at acute-phase exit. Limitations: Population norms are yet undefined. Concurrent validity with detailed, well-validated scales that assess the seven Quality of Life domains incorporated in the Mini-Q-LES-Q remains unestablished. Sensitivity to symptom changes induced by psychotherapy or somatic therapies or sensitive to the effects of therapies aimed at enhancing quality of life enjoyment and function is unknown. Conclusion: The 7-item Mini-Q-LES-Q self-report measure satisfaction/quality of life has acceptable psychometric properties, reflects change with depressive symptom reduction, and detects residual deficits in this key clinical outcome.
AB - Objective: To develop and evaluate a new brief self-report measure of satisfaction/quality of life in depressed outpatients. Methods: Using the Quality of Life Enjoyment and Satisfaction Questionnaire Short-Form (Q-LES-Q-SF) self-report from Step-1 (n = 2181) of the STAR*D trial, items were selected based on their magnitude of change with treatment and correlation with 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16). Psychometric analyses were conducted. Replication of scale performance was assessed with STAR*D Step-2 data (n = 250). Results: The 7 items selected (“Mini-Q-LES-Q”) rated satisfaction with work, household activities, social and family relations, leisure time activities, daily function and sense of well-being in the past week. This uni-dimensional scale captured 83–94% variance in Q-LES-Q-SF and had acceptable Item Response and Classical Test Theory characteristics. Baseline to exit percent changes in the Mini-Q-LES-Q and the QIDS-SR16 were significantly, modestly related (r = -0.552) (Step-1) and replicated (r = -0.562) (Step-2). The Mini-Q-LES-Q detected the expected improvement in satisfaction/quality of life in acute treatment, yet also identified residual deficits expected in many at acute-phase exit. Limitations: Population norms are yet undefined. Concurrent validity with detailed, well-validated scales that assess the seven Quality of Life domains incorporated in the Mini-Q-LES-Q remains unestablished. Sensitivity to symptom changes induced by psychotherapy or somatic therapies or sensitive to the effects of therapies aimed at enhancing quality of life enjoyment and function is unknown. Conclusion: The 7-item Mini-Q-LES-Q self-report measure satisfaction/quality of life has acceptable psychometric properties, reflects change with depressive symptom reduction, and detects residual deficits in this key clinical outcome.
KW - Depression
KW - Function
KW - Psychosocial outcomes
KW - Quality of life
KW - Recovery
KW - Satisfaction
KW - Self-report
UR - http://www.scopus.com/inward/record.url?scp=85052536837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052536837&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2018.08.052
DO - 10.1016/j.jad.2018.08.052
M3 - Article
C2 - 30173063
AN - SCOPUS:85052536837
SN - 0165-0327
VL - 242
SP - 87
EP - 95
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
ER -